Laris Galejs, MD
Urology · Cadillac, MINPI 1053304600
Payments from drug & device makers
Across 140 payments — averaging $48.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Dendreon Pharmaceuticals LLC$645
- Medtronic$632
- Ferring Pharmaceuticals Inc.$496
- Astellas Pharma US Inc$359
- AbbVie$281
- plus $2K from 26 others
What the payments were for
- Consulting fees$5007%
- Travel & lodging$2,07030%
- Food & beverage$4,13161%
- Education$881%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 25 | $2,796 |
| Dendreon Pharmaceuticals LLC | 2 | $645 |
| Medtronic(2 entities) | 10 | $632 |
| Ferring Pharmaceuticals Inc. | 5 | $496 |
| Astellas Pharma US Inc | 20 | $359 |
| AbbVie(2 entities) | 12 | $281 |
| Olympus America Inc. | 6 | $227 |
| Calyxo, Inc. | 2 | $155 |
| Johnson & Johnson | 3 | $154 |
| Pfizer | 21 | $133 |
| Coloplast | 5 | $103 |
| Sanofi | 1 | $102 |
| Merck | 1 | $96 |
| Tolmar Pharmaceuticals, Inc. | 1 | $87 |
| Blue Earth Diagnostics | 4 | $73 |
| Myriad Genetic Laboratories, Inc. | 3 | $68 |
| Intuitive Surgical | 2 | $65 |
| Teleflex LLC | 1 | $37 |
| Photocure Inc | 2 | $35 |
| Janssen Scientific Affairs, LLC | 1 | $28 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $28 |
| Endo Pharmaceuticals Inc. | 2 | $27 |
| Novo Nordisk | 1 | $21 |
| Urogen Pharma, Inc. | 1 | $20 |
| Axonics, Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Dentsply IH Inc. | 1 | $15 |
| SRS Medical Systems, Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $13 |
| Procept Biorobotics Corporation | 1 | $13 |
| Rochester Medical Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$645
- AdVance XP$528
- FIRMAGON$487
- INTERSTIM$438
- AMS 700$275
- BOTOX$144
- CVAC Aspiration System$138
- iTIND System$109
- JEVTANA$102
How this compares
$6,789 in reported general payments places this provider in the 70th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 104 | $69,259 |
| MyrbetriqMirabegron | 120 | $62,384 |
| Tamsulosin Hcl | 315 | $5,420 |
| Silodosin | 55 | $3,483 |
| Potassium Citrate ErPotassium Citrate | 22 | $2,405 |
| Dutasteride | 47 | $1,592 |
| Oxybutynin Chloride ErOxybutynin Chloride | 84 | $1,285 |
| Finasteride | 78 | $1,115 |
| Fosfomycin Tromethamine | 14 | $782 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 24 | $687 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 37 | $615 |
| Solifenacin Succinate | 16 | $516 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 65 | $287 |
| Cephalexin | 35 | $153 |
| Ciprofloxacin Hcl | 36 | $121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $18 | $69,259104 claims |
| Astellas Pharma US IncMyrbetriq | $359 | $62,384120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 400 urology providers in Michigan.
Other urology in Cadillac
- Jason HafronWest Bloomfield$9.9M
- Ashok ReddySterling Heights$4.9M
- Kenneth KernenTroy$3.4M
- James PeabodyDetroit$2.1M
- William RobertsAnn Arbor$973K
- Adam GadzinskiRoyal Oak$727K
- William JohnstonLivonia$675K
- Kenneth PetersRoyal Oak$590K
- Khurshid GhaniAnn Arbor$550K
- Richard BennettRoyal Oak$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.